U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Why now
Thesis: FDA approval adds new Lilly revenue path in ER+ breast cancer
Catalyst to watch: Launch uptake and payer coverage decisions
Main risk: Competitive SERD entrants and pricing pressure
Why it matters
An FDA approval expands the label for Lilly's oral SERD plus Verzenio, adding a new revenue path in ER+ breast cancer after CDK4/6 progression.
Details
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free...
Sources
- prnewswire · 2026-09-18 17:54 UTC